Atazanavir Krka

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Descarcare Prospect (PIL)
07-06-2023

Ingredient activ:

atazanavir (as sulfate)

Disponibil de la:

Krka, d.d., Novo mesto

Codul ATC:

J05AE08

INN (nume internaţional):

atazanavir

Grupul Terapeutică:

Antivirals for systemic use

Zonă Terapeutică:

HIV Infections

Indicații terapeutice:

Atazanavir Krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).The choice of Atazanavir Krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

Rezumat produs:

Revision: 2

Statutul autorizaţiei:

Authorised

Data de autorizare:

2019-03-25

Prospect

                                53
B. PACKAGE LEAFLET
54
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ATAZANAVIR KRKA 150 MG HARD CAPSULES
ATAZANAVIR KRKA 200 MG HARD CAPSULES
ATAZANAVIR KRKA 300 MG HARD CAPSULES
atazanavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Atazanavir Krka is and what it is used for
2.
What you need to know before you take Atazanavir Krka
3.
How to take Atazanavir Krka
4.
Possible side effects
5.
How to store Atazanavir Krka
6.
Contents of the pack and other information
1.
WHAT ATAZANAVIR KRKA IS AND WHAT IT IS USED FOR
ATAZANAVIR KRKA IS AN ANTIVIRAL (OR ANTIRETROVIRAL) MEDICINE. It is
one of a group called _protease _
_inhibitors_. These medicines control Human Immunodeficiency Virus
(HIV) infection by stopping a
protein that the HIV needs for its multiplication. They work by
reducing the amount of HIV in your
body and this in turn, strengthens your immune system. In this way
Atazanavir Krka reduces the risk
of developing illnesses linked to HIV infection.
Atazanavir Krka capsules may be used by adults and children 6 years of
age and older. Your doctor
has prescribed Atazanavir Krka for you because you are infected by the
HIV that causes Acquired
Immunodeficiency Syndrome (AIDS). It is normally used in combination
with other anti-HIV
medicines. Your doctor will discuss with you which combination of
these medicines with Atazanavir
Krka is best for you.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ATAZANAVIR KRKA
DO NOT TAKE ATAZANAVIR KRKA
-
IF YOU ARE ALLERGIC to atazanavir or any of the other ingr
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atazanavir Krka 150 mg hard capsules
Atazanavir Krka 200 mg hard capsules
Atazanavir Krka 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_Atazanavir Krka 150 mg hard capsules_
Each hard capsule contains 150 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 79.43 mg lactose monohydrate.
_Atazanavir Krka 200 mg hard capsules_
Each hard capsule contains 200 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 105.91 mg lactose monohydrate.
_Atazanavir Krka 300 mg hard capsules_
Each hard capsule contains 300 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 158.86 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule)
_Atazanavir Krka 150 mg hard capsules_
Hard gelatine capsule, size no. 1. The body of the capsule is white or
almost white colour, the cap of
the capsule is brownish-orange colour. The capsule cap is imprinted
with black mark A150. The
content of the capsule is yellowish-white to yellow-white powder.
_Atazanavir Krka 200 mg hard capsules_
Hard gelatine capsule, size no. 0. The body and the cap of the capsule
are brownish-orange colour.
The capsule cap is imprinted with black mark A200. The content of the
capsule is yellowish-white to
yellow-white powder.
_Atazanavir Krka 300 mg hard capsules_
Hard gelatine capsule, size no. 00. The body of the capsule is white
or almost white colour, the cap of
the capsule is dark brown colour. The capsule cap is imprinted with
white mark A300. The content of
the capsule is yellowish-white to yellow-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Atazanavir Krka capsules, co-administered with low dose ritonavir, are
indicated for the treatment of
HIV-1 infected adults and paediatric patients 6 years of age and older
in combination with other
antiretroviral medicinal products (see section 4.2).

                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 07-06-2023
Raport public de evaluare Raport public de evaluare bulgară 15-05-2019
Prospect Prospect spaniolă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 07-06-2023
Raport public de evaluare Raport public de evaluare spaniolă 15-05-2019
Prospect Prospect cehă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 07-06-2023
Raport public de evaluare Raport public de evaluare cehă 15-05-2019
Prospect Prospect daneză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 07-06-2023
Raport public de evaluare Raport public de evaluare daneză 15-05-2019
Prospect Prospect germană 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului germană 07-06-2023
Raport public de evaluare Raport public de evaluare germană 15-05-2019
Prospect Prospect estoniană 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 07-06-2023
Raport public de evaluare Raport public de evaluare estoniană 15-05-2019
Prospect Prospect greacă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 07-06-2023
Raport public de evaluare Raport public de evaluare greacă 15-05-2019
Prospect Prospect franceză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 07-06-2023
Raport public de evaluare Raport public de evaluare franceză 15-05-2019
Prospect Prospect italiană 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 07-06-2023
Raport public de evaluare Raport public de evaluare italiană 15-05-2019
Prospect Prospect letonă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 07-06-2023
Raport public de evaluare Raport public de evaluare letonă 15-05-2019
Prospect Prospect lituaniană 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 07-06-2023
Raport public de evaluare Raport public de evaluare lituaniană 15-05-2019
Prospect Prospect maghiară 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 07-06-2023
Raport public de evaluare Raport public de evaluare maghiară 15-05-2019
Prospect Prospect malteză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 07-06-2023
Raport public de evaluare Raport public de evaluare malteză 15-05-2019
Prospect Prospect olandeză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 07-06-2023
Raport public de evaluare Raport public de evaluare olandeză 15-05-2019
Prospect Prospect poloneză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 07-06-2023
Raport public de evaluare Raport public de evaluare poloneză 15-05-2019
Prospect Prospect portugheză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 07-06-2023
Raport public de evaluare Raport public de evaluare portugheză 15-05-2019
Prospect Prospect română 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului română 07-06-2023
Raport public de evaluare Raport public de evaluare română 15-05-2019
Prospect Prospect slovacă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 07-06-2023
Raport public de evaluare Raport public de evaluare slovacă 15-05-2019
Prospect Prospect slovenă 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 07-06-2023
Raport public de evaluare Raport public de evaluare slovenă 15-05-2019
Prospect Prospect finlandeză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 07-06-2023
Raport public de evaluare Raport public de evaluare finlandeză 15-05-2019
Prospect Prospect suedeză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 07-06-2023
Raport public de evaluare Raport public de evaluare suedeză 15-05-2019
Prospect Prospect norvegiană 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 07-06-2023
Prospect Prospect islandeză 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 07-06-2023
Prospect Prospect croată 07-06-2023
Caracteristicilor produsului Caracteristicilor produsului croată 07-06-2023
Raport public de evaluare Raport public de evaluare croată 15-05-2019

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor